Project Grant R01DK144134
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of Alabama at Birmingham a $1.93 million Project Grant on March 4, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a 10-year follow-up study of the Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD FU) Study. The project, with completion targeted for February 28, 2031, will...
- Federal Project Grant Award Summary Vanderbilt University Medical Center (VUMC) received a $143,346 project grant awarded July 15, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports a transdisciplinary research initiative examining gestational weight gain and its maternal-child health outcomes. The research employs three primary methodologies:...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded $129,619 to the University of Colorado-Denver on September 1, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This Project Grant funds investigator-initiated biomedical research examining the interactions between the gut microbiome, intestinal development, and metabolic health outcomes following fetal growth restriction...
- Federal Project Grant Award Summary The University of Pittsburgh received a $521,829 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 4, 2025, with a completion date of June 30, 2029. The award funds basic biomedical research investigating hepatic prolactin receptor (PRLR) signaling and its role in maternal metabolic adaptation during...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $240,978 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 1, 2025, with completion expected by August 31, 2027. This research project will deliver transcriptional, regulatory, and spatial analysis of kidney development changes during mid to late...
- Federal Project Grant Award Summary Vanderbilt University received a $104,865 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective December 13, 2025, through August 31, 2027. The research investigates the role of PDX1 (Pancreatic and Duodenal Homeobox 1) C-terminal interaction domains in pancreatic endocrine cell differentiation and...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $786,216 Project Grant to the University of California, Los Angeles (UCLA) on August 28, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports a four-year research initiative (through June 30, 2029) investigating post-transcriptional regulation of hepatokines and systemic metabolism. The research focuses on identifying...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded $118,125 to the University of California, Los Angeles (UCLA) Office of Research Administration on February 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds a two-year research project concluding January 31, 2028, focused on identifying pregnancy-related hepcidin-suppressing hormones and regulatory mechanisms...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $672,737 Project Grant to the University of California, Los Angeles (UCLA) on August 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research will be conducted through July 31, 2030, at UCLA's Los Angeles campus. This award supports basic biomedical research investigating the molecular mechanisms by which...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $177,986 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 9, 2025, with a completion date of July 31, 2030. The grant funds a pilot Phase II clinical trial investigating the efficacy of tirzepatide (TRZ), a glucagon-like peptide-1 receptor agonist, as an adjuvant...
Vanderbilt University Medical Center received a $449,242 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective May 1, 2026 through April 30, 2028. This award supports research investigating the effects of maternal metformin exposure and dietary patterns on fetal pancreatic islet beta-cell development and function using a translational non-human primate model. The research will utilize existing maternal-offspring phenotyping data and biological samples collected through a parent R01 award to characterize developmental impacts on offspring islet mitochondrial health, gene regulation, cell identity, and insulin secretion capacity. The project addresses clinical concerns regarding increased metformin use during pregnancy beyond maternal diabetes treatment, given evidence linking fetal metformin exposure to reduced birth weight and increased childhood metabolic dysfunction risk. Using rhesus macaques exposed to clinically relevant metformin doses combined with either healthy or Western-style diet conditions, the research will elucidate mechanisms by which maternal metformin and dietary exposures may disrupt developmental programming of offspring glucose homeostasis and diabetes risk. The deliverables include comprehensive characterization of fetal islet phenotypes, metabolic outputs, and functional assessments intended to inform clinical guidance on metformin safety during pregnancy.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $449.2k | 5/5/26 |